Network Understanding of Herb Medicine via Rapid Identification of Ingredient-Target Interactions

[1]  A. Azmi.  Adopting network pharmacology for cancer drug discovery. , 2013, Current drug discovery technologies.

[2]  David S. Goodsell,et al.  The RCSB Protein Data Bank: new resources for research and education , 2012, Nucleic Acids Res..

[3]  T. Gao,et al.  [Meta-analysis on treatment of non-small cell lung cancer with brucea javanica oil emulsion in combination with platinum-contained first-line chemotherapy]. , 2012, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[4]  J. Feliu,et al.  ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications. , 2012, International journal of oncology.

[5]  S. Sizemore,et al.  The Forkhead Box Transcription Factor FOXC1 Promotes Breast Cancer Invasion by Inducing Matrix Metalloprotease 7 (MMP7) Expression* , 2012, The Journal of Biological Chemistry.

[6]  Tamas Hickish,et al.  A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab , 2012, Breast Cancer Research and Treatment.

[7]  Yilong Wu,et al.  非小细胞肺癌的BRAF基因突变及其临床意义 , 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[8]  M. Zorzetto,et al.  Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. , 2012, Respiratory medicine.

[9]  H. Nielsen,et al.  TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity , 2012, Scandinavian journal of gastroenterology.

[10]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[11]  K. Kunimasa,et al.  Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. , 2012, Internal medicine.

[12]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Ochi,et al.  Ubiquitination and downregulation of ErbB2 and estrogen receptor‐alpha by kinase inhibitor MP‐412 in human breast cancer cells , 2011, Journal of cellular biochemistry.

[14]  Xue-jun Cui,et al.  Classic yin and yang tonic formula for osteopenia: study protocol for a randomized controlled trial , 2011, Trials.

[15]  Fan Zhou,et al.  Seed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related Pathways , 2011, Evidence-based complementary and alternative medicine : eCAM.

[16]  Jing Yuan,et al.  非小细胞肺癌治疗的新靶点：EML4-ALK融合基因 , 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[17]  Jason J Chen,et al.  Tumor Cell Selective Cytotoxicity and Apoptosis Induction by an Herbal Preparation from Brucea javanica. , 2011, North American journal of medicine & science.

[18]  S. Zienolddiny,et al.  A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. , 2011, Lung cancer.

[19]  Donna D. Zhang,et al.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism , 2011, Proceedings of the National Academy of Sciences.

[20]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[21]  Jongsun Park,et al.  Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer. , 2010, World journal of biological chemistry.

[22]  W. W. Hsiao,et al.  The Role of Traditional Chinese Herbal Medicines in Cancer Therapy – from TCM Theory to Mechanistic Insights , 2010, Planta medica.

[23]  Zhuomei Lu,et al.  3-Phosphoinositide–Dependent Protein Kinase-1 Regulates Proliferation and Survival of Cancer Cells with an Activated Mitogen-Activated Protein Kinase Pathway , 2010, Molecular Cancer Research.

[24]  Gudrun Ulrich-Merzenich,et al.  Drug development from natural products: exploiting synergistic effects. , 2010, Indian journal of experimental biology.

[25]  H. Yao,et al.  Brucea javanica oil induces apoptosis in T24 bladder cancer cells via upregulation of caspase-3, caspase-9, and inhibition of NF-kappaB and COX-2 expressions. , 2010, The American journal of Chinese medicine.

[26]  André Schrattenholz,et al.  Systems biology approaches and tools for analysis of interactomes and multi-target drugs. , 2010, Methods in molecular biology.

[27]  P. Leung,et al.  Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. , 2009, Cancer letters.

[28]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[29]  A. Tardón,et al.  Polymorphism +17 C/G in Matrix Metalloprotease MMP8 decreases lung cancer risk , 2008, BMC Cancer.

[30]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[31]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[32]  Jun-quan Yang,et al.  [Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer]. , 2008, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[33]  Florian Kronenberg,et al.  Matrix Metalloproteinase 1 (MMP1) Is Associated with Early-Onset Lung Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[34]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[35]  Z R Li,et al.  MODEL—molecular descriptor lab: A web‐based server for computing structural and physicochemical features of compounds , 2007, Biotechnology and bioengineering.

[36]  Meixian Jiang.  The TCM stage-oriented treatment for chronic cardiac insufficiency. , 2007, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[37]  A. Hopkins.  Network pharmacology , 2007, Nature Biotechnology.

[38]  Y. Z. Chen,et al.  Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation , 2006, British journal of pharmacology.

[39]  T. Furukawa,et al.  AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer , 2006, Oncogene.

[40]  A. Chan,et al.  Antiproliferative and apoptosis-inducing activity of Brucea javanica extract on human carcinoma cells. , 2005, International journal of molecular medicine.

[41]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[42]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[43]  J. Pezzuto,et al.  Brusatol-induced HL-60 cell differentiation involves NF-κB activation , 2004 .

[44]  J. Pezzuto,et al.  Antitumor activity of bruceantin: an old drug with new promise. , 2004, Journal of natural products.

[45]  J. Pezzuto,et al.  Multiple Myeloma Regression Mediated by Bruceantin , 2004, Clinical Cancer Research.

[46]  S. Nakagawa,et al.  Bruceine B, A Potent Inhibitor of Leukocyte-Endothelial Cell Adhesion , 1997, Inflammation.

[47]  J. Pezzuto,et al.  Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. , 2004, Cancer letters.

[48]  J. Wolter,et al.  A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma , 2004, Investigational New Drugs.

[49]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[50]  E. Green,et al.  Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. , 2002, Blood.

[51]  C Y Ung,et al.  Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants. , 2002, The American journal of Chinese medicine.

[52]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[54]  R. Lock,et al.  The potential tumour suppressor role for caspase-9 (CASP9) in the childhood malignancy, neuroblastoma. , 2001, European journal of cancer.

[55]  P. Hasleton,et al.  Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. , 1986, British Journal of Cancer.

[56]  K. Lee,et al.  Anti-inflammatory agents III: Structure-activity relationships of brusatol and related quassinoids. , 1983, Journal of pharmaceutical sciences.

[57]  C. Wiseman,et al.  Phase II trial of bruceantin in metastatic breast carcinoma , 1982, American journal of clinical oncology.

[58]  K. Lee,et al.  Antitumor agents XLVI: In vitro effects of esters of brusatol, bisbrusatol, and related compounds on nucleic acid and protein synthesis of P-388 lymphocytic leukemia cells. , 1982, Journal of pharmaceutical sciences.

[59]  A. Gonzales,et al.  Bruceantin, a novel inhibitor of peptide bond formation. , 1978, Biochimica et biophysica acta.

[60]  S. M. Kupchan,et al.  Structural requirements for biological activity among antileukemic glaucarubolone ester quassinoids. , 1976, Journal of medicinal chemistry.